DNTH Earnings & Financial Statements
Dianthus Therapeutics, Inc.
$75.94
+$1.18(+1.58%)
43
Overall
60
Value
27
Tech
44
Quality
Market Cap
$4.18B
Volume
88.04K
52W Range
$32.22 - $117.88
Target Price
$140.13
DNTH earnings and financial statements: Dianthus Therapeutics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
DNTH Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $2.04M | $6.24M | $2.83M | $6.42M | - |
| Operating income | -$177.93M | -$101.86M | -$48.17M | -$29.70M | -$74.69M |
| EBITDA | -$161.92M | -$84.55M | -$47.82M | -$29.56M | -$13.09M |
| Net income | -$162.34M | -$84.97M | -$43.55M | -$28.48M | -$13.11M |
| EPS (diluted) | $-4.20 | $-2.55 | $-8.45 | $-20.64 | $-20.64 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $530.92M | $374.01M | $179.41M | $83.11M | $189.93M |
| Total liabilities | $37.52M | $21.53M | $10.54M | $9.45M | $17.26M |
| Shareholders’ equity | $493.40M | $352.48M | $168.87M | -$44.37M | $172.67M |
| Cash and equivalents | $51.09M | $22.79M | $132.32M | $15.37M | $131.65M |
| Long-term debt | $1.02M | $1.17M | $168.0K | $438.0K | - |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$129.06M | -$78.18M | -$36.86M | -$29.07M | -$9.90M |
| Capital expenditure | -$213.0K | -$105.0K | -$110.0K | -$139.0K | -$33.0K |
| Free cash flow | -$129.27M | -$78.28M | -$36.97M | -$29.21M | -$9.94M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | DNTH | $75.94 | +1.6% | 88.04K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Dianthus Therapeutics, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW